This latter type of treatment is associated with a more rapid response but can only be used in melanomas that harbour an activating BRAF V600E mutation, and, unfortunately, resistance to treatment installs rapidly, after a median duration of 11 months [48,49,50,51,52,53]. Here, BRAF is linked to melanoma.